CATEGORY: Press Release

Expands use of Nociscan in groundbreaking trial with Roger Härtl, MD BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success […]

Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026 Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwide Announced $2.5 million share repurchase program Strong balance sheet, no debt and cash runway […]

Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologies Expansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo. — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers […]

Highlights Disciplined Capital Allocation While Supporting Continued Nociscan® Adoption BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced […]

Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and […]

Expands use of Nociscan in groundbreaking trial BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine. […]

Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging […]

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging […]

Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify […]

Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo. — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company […]